NCT07058519 2025-11-26
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Shanghai Chest Hospital
Phase 2 Recruiting
Clinical Trials
1 trialsLocally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) × osimertinib × 1 year × Clear all